Drug Profile
Azeloprazole - Eisai
Alternative Names: E-3710; Z 215Latest Information Update: 08 Sep 2021
Price :
$50
*
At a glance
- Originator Eisai Co Ltd
- Developer Eisai Co Ltd; SFJ Pharmaceuticals; Zeria
- Class Antiulcers; Gastric antisecretories
- Mechanism of Action Proton pump inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gastro-oesophageal reflux
- No development reported Erosive oesophagitis
Most Recent Events
- 08 Sep 2021 No development reported - Phase-II for Erosive oesophagitis in Japan (PO)
- 08 Sep 2021 SFJ Pharmaceuticals completes a phase II trial in Gastro-oesophageal reflux in USA (PO), prior to September 2021 (SFJ Pharmaceuticals pipeline, September 2021)
- 28 Feb 2019 No recent reports of development identified for phase-I development in Erosive-oesophagitis(In volunteers) in United Kingdom (PO, Liquid)